Jing Xi, MD, MPH


Medical Oncologist / Hematologist

Jing Xi, MD, MPH | Oncologist at Rocky Mountain Cancer Centers

Littleton

22 W. Dry Creek Cir.
Littleton, Colorado 80120

303-730-4700

Request an Appointment


SECONDARY LOCATION(S)

Aurora

1700 S. Potomac St.
Aurora, Colorado 80012

303-418-7600

Request an Appointment

Centennial

14000 E. Arapahoe Rd., Ste. 160
Centennial, Colorado 80112

303-805-7744

Request an Appointment

Englewood - Swedish Medical Center

499 E. Hampden Ave., Ste. 450
Englewood, Colorado 80113

303-740-8200

Request an Appointment

Littleton Breast Specialists

22 W. Dry Creek Cir.
Littleton, Colorado 80120

303-376-5020

Request an Appointment

Aurora Breast Specialists

1700 S. Potomac St.
Aurora, Colorado 80012

303-376-5020

Request an Appointment

Centennial Breast Specialists

14000 E. Arapahoe Rd., Ste. 160
Centennial, Colorado 80112

303-376-5020

Request an Appointment

Englewood Swedish Medical Center Breast Specialists

499 E. Hampden Ave., Ste. 450
Englewood, Colorado 80113

303-376-5020

Request an Appointment

About Jing Xi, MD, MPH

Dr. Jing Xi is a board-certified medical oncologist who joined Rocky Mountain Cancer Centers in 2022. Her clinical practice is dedicated to the care of patients with breast cancer. Her clinical and research interests are in molecular mechanisms of resistance to targeted therapy in metastatic breast cancer. She has contributed extensively to breast cancer research, including authoring and co-authoring peer-reviewed journal articles, oncology conference abstracts, and oncology book chapters. In addition to being actively involved in clinical research, Dr. Xi remains up to date on the most recent treatment advancements and cutting-edge therapies.

Dr. Xi’s goal at each clinic visit is to help navigate the cancer care journey together with her patients by guiding patients through their diagnosis and providing clear and comprehensive education on treatment options, including the latest clinical trials. This is to make sure that her patients can feel confident making informed decisions about their care.

Dr. Xi is an active member of several weekly tumor boards and multi-disciplinary clinics, where she works closely with other cancer specialists including breast imaging, surgical oncology, radiation oncology, and plastic surgery, to review patient cases, share knowledge, and determine the best possible treatment for each patient. This collaborative approach helps to deliver the highest quality of cancer care. 

As a women’s health specialist, Dr. Xi also specializes in treating gynecologic cancers including cervical, endometrial, ovarian, uterine, and vulvar cancers. As a board-certified hematologist, Dr. Xi also treats blood disorders including, but not limited to, bleeding disorders, clotting disorders, and iron deficiency anemia.

Board Certifications

Hematology (B.E)
Internal Medicine
Medical Oncology (B.E)

Clinical Care Expertise

  • Blood Disorders
    • Anemia
    • Antiplatelet and Anticoagulant Management
    • Bleeding & Clotting Disorders
    • Iron Deficiency
    • Pregnancy -Related Blood Disorders
    • Surgical Clearances
    • Thrombocytopenia
  • Breast Cancers
    • Atypical Ductal Hyperplasia
    • Atypical Lobular Hyperplasia
    • Ductal Carcinoma in Situ (DCIS)
    • HER2+ Breast Cancers
    • Inflammatory Breast Cancer
    • Invasive Breast Cancer (IDC/ILC)
    • Lobular Carcinoma in Situ (LCIS)
    • Metastatic Breast Cancer
    • Paget Disease of the Breast
    • Triple-Negative Breast Cancer
  • Cancer Genetics
  • Clinical Research
  • High Risk Breast Cancer Prevention
  • Gynecologic Cancers
    • Cervical Cancer
    • Ovarian Cancer
    • Uterine Cancer
    • Vaginal Cancer
    • Vulvar Cancer

Education

Fellowship

Medical Oncology/Hematology, Washington University, St. Louis, MO

Residency

Internal Medicine, St. Luke’s Hospital, Chesterfield, MO

Medical School

Fudan University, Shanghai, China

Patient Care Philosophy

I am dedicated to delivering personalized care to improve patient outcomes and quality of life. I offer a tailored therapeutic approach based on each patient’s specific tumor biology and side-effect profile, which yields better treatment response and tolerability. I integrate the latest advances in science into patient care. I take care of my patients as a whole person, including not only their physical health, but also emotional health, and in some patients, reproductive health during their treatment with chemotherapy and endocrine therapy.

Languages Spoken

  • Chinese (Standard Mandarin)
  • English

Additional Information

American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
American Medical Association (AMA)
Chinese American Hematologist and Oncologist Network (CAHON)
European Society for Medical Oncology (ESMO)

Xi, J., Luo, J., O’Sullivan, C., Chen, N., Stringer-Reasor, E., Ma, C., Campian, J. Phase II Study of the
Combination of Liposomal Irinotecan and Pembrolizumab for Triple-Negative Breast Cancer with Brain
Metastases. 2022 Annual Conference on CNS Clinical Trials and Brain Metastases. Toronto, Canada.
Aug 12-13, 2022

Xi, J., Harnden, K., Call, G., Mauer, E., Ronski, K., Luo, J., Ma, C*, and Vasan, N. Genomic landscape of
HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations. St.
Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX. Dec 7-10, 2021

Brett, J., Dubash, T., Niemierko, A., Mariotti, V., Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A.,
Lloyd, MR., Spring, LM., Micalizzi, D., Onozato, M., Che, D., Brufsky, A., Kalinsky, K., Ma, CX.,
O’Shaughnessy, J., Han, HS., Iafrate, J., Maheswaran, S., Haber, DA., Bardia, A., Wander, SA. Association
between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone
receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine
therapy plus palbociclib or ribociclib. St. Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX.
Dec 7-10, 2021 [spotlight poster]

Xi, J., Bagegni, N., Ademuyiwa, F., Frith, A., Suresh, R., Roshal, A., Rigden, C., Hernandez-Aya, L.,
Peterson, L., Opyrchal, M., Clifton, K., Weilbaecher, K., Bose, R., Ma CX. Circulating tumor DNA
mutation profile in relation to palbociclib efficacy in hormone receptor positive and HER2 negative
metastatic breast cancer. St. Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX. Dec 8-12,
2020

Wander, S., Han, H., Johnson, G., Lloyd, M., Mao, P., Nayar, U., Kowalski, K., Stein, C., Mariotti, Kim, L.,
Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Brufsky, A., Kalinsky, K., Ma, C., O’Shaughnessy, J., Wagle,
N., Bardia, A. ESR1 mutation as a potential predictor of abemaciclib benefit following prior CDK4/6
inhibitor (CDK4/6i) progression in hormone receptor-positive (HR+) metastatic breast cancer (MBC): a
translational investigation. St. Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX. Dec 8-12,
2020

Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C.,
Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C.,
O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in
Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. American Society of Clinical
Oncology (ASCO) Meeting, Chicago, IL. May 31 – June 4, 2019. Same abstract published in JCO 2019; 37
(15_Suppl)

Xi, J.*, Oza, A.*, Thomas, S., Naughton, M., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R.,
Cherian, M., Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective
Review of Palbociclib Efficacy and Benefit from Subsequent Treatments Following Palbociclib
Progression in Patients with Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer.
St. Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX. Dec 5-9, 2017. Same abstract published
in AACR 2018; 78(4_Suppl)

Tavris, D., Wang, C., Chu H., Xi J., Nie L., Jacobs S., Duggirala H., Pinnow E. Assessing Publication Bias
from Clinical Studies of Coronary Artery Stents. International Society for Pharmacoepidemiology (ISPE)
Annual Conference, Chicago, IL. Aug 14-17, 2011

Xi, J. An Overlooked Sexual Orientation Health Disparities in Female Breast Cancer Screening. The
Michigan Meeting 2010: The Economy and Cancer Health Disparities, Ann Arbor, MI. May 20-22, 2010

Peer-reviewed Journal Articles

Brett, J., Dubash, T., Johnson, G., Niemierko, A., Mariotti, V., Kim, L., Xi, J., Pandey, A., Dunne, S.,
Nasrazadani, A., Lloyd, M., Kambadadone, A., Spring, L., Micalizzi, D., Onozato, M., Che, D., Nayar, U.,
Brufksy, A., Kalinsky, K., Ma, C., O'Shaughnessy, J., Han, H., Iafrate, A., Ryan, L., Juric, D., Moy, B., Ellisen,
L., Maheswaran, S., Wagle, N., Haber, D., Bardia, A., and Wander S. Clinical Cancer Research (CCR).
2022. [under review]

Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C.,
Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C.,
O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in
Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. Journal of the National
Comprehensive Cancer Network (JNCCN) 2021 Mar 24:1-8: [Epub ahead of print]

Xi, J.*, Hassan, B.*, Katumba, R., Khaddour, K., Govindan, A., Luo, J., Huang, J., Campian, JL. The
Predictive Value of Absolute Lymphocyte Counts on Tumor Progression and Pseudoprogression in
Patients with Glioblastoma. BMC Cancer 2021 Mar 16:21(1): 285

Xi, J., Cynthia X. Ma. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do
After Disease Progression on a CDK4/6 Inhibitor? Current Oncology Reports 2020; 22 (6): 57.

Xi, J.*, Oza, A.*, Thomas, S., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R., Cherian, M.,
Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective Analysis of
Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast
Cancer. Journal of the National Comprehensive Cancer Network (JNCCN) 2019; 17(2): 141-147.

Patel, D.*, Xi, J.*, Luo, J., Ma, C., Campian, J. Neutrophil to Lymphocyte Ratio as a Predictor of Survival
in Patients with Triple-Negative Breast Cancer. Breast Cancer Research and Treatment 2019; 174(2):
443-452.

Yang, C.*, Xi, J.*, Sheikh, S., Hakim, A., Nadella, S., Dhital, S., MD; Meier, M., Nnanna, O., Meyers, D. A
Scoring System for Prediction and Risk Stratification of CO2 Narcosis Among Hospitalized Patients.
Emergency Medicine 2018; 8(2):368.

Book Chapters

Xi, J., Ma, C., Clifton, K. Chapter 13. Breast Cancer. The Washington Manual of Oncology. 4th edition.
2021

Committee on Review of California Institute for Regenerative Medicine (CIRM) (Group Author). The
California Institute for Regenerative Medicine: Science, Governance, and the Pursuit of Cures. 2012.
Washington, DC: The National Academies Press.

Committee on Advancing Pain Research, Care, and Education (Group Author). Relieving Pain in America
– A Blueprint for Transforming